Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia-Reference-Cited by-同舟云学术

Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia

Published:2019-08-15 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Yoon Jae-Ho,Kim Hee-Je,Min Gi June,Park Sung-Soo^ORCID,Jeon Young-Woo^ORCID,Lee Sung-Eun,Cho Byung-Sik,Eom Ki-Seong,Kim Yoo-Jin,Lee Seok,Min Chang-Ki,Cho Seok-Goo^ORCID,Lee Jong Wook

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-019-47937-4.pdf

Reference26 articles.

1. Sanz, M. A. et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 94, 3015–3021 (1999).

2. Mandelli, F. et al. Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia 17, 1085–1090, https://doi.org/10.1038/sj.leu.2402932 (2003).

3. Grimwade, D. et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116, 354–365, https://doi.org/10.1182/blood-2009-11-254441 (2010).

4. Sanz, M. A. et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 115, 5137–5146, https://doi.org/10.1182/blood-2010-01-266007 (2010).

5. Ades, L. et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 24, 5703–5710, https://doi.org/10.1200/JCO.2006.08.1596 (2006).

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leucocytosis during induction therapy with all‐trans‐retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment‐related complications;British Journal of Haematology;2024-09-14

2. Early predictor for differentiation syndrome in newly diagnosed acute promyelocytic leukaemia patients treated with single-agent arsenic trioxide;Annals of Hematology;2024-04-29

3. Improved Prevention and Treatment Strategies for Differentiation Syndrome Contribute to Reducing Early Mortality in Patients With Acute Promyelocytic Leukemia;2024-04-08

4. Effectiveness of leukapheresis on early survival in acute myeloid leukemia: An observational propensity score matching cohort study;Journal of Clinical Apheresis;2023-10-03

5. Differentiation Syndrome in Acute Leukemia: APL and Beyond;Cancers;2023-09-28